Course of Multimodal Therapy and Genetic Profile of Hereditary Leiomyomatosis and Renal Cell Carcinoma with Early Recurrence during Adjuvant Therapy after Radical Nephrectomy: A Case Report
Urologia Internationalis · 2025
DOI: 10.1159/000547393 ↗Kurz gefasst
Fallbericht in der Zeitschrift Urologia Internationalis, 2025. Verfasst von Hiroshi Masuda und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan. Hauptthemen laut MEDLINE: Leiomyomatosis, Nephrectomy, Neoplasm Recurrence, Local, Kidney Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Fumarate hydratase-deficient renal cell carcinoma is a rare and aggressive subtype associated with hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome, characterized by germline mutations in the fumarate hydratase (FH) gene. Here, we report a case of HLRCC with early recurrence during adjuvant therapy following radical nephrectomy. Case Presentation: A 34-year-old woman with FH-deficient RCC presented with fever, right flank pain, and a large renal mass with a tumor thrombus. Open radical nephrectomy and IVC tumor thrombectomy were performed. Pathological findings and genetic analyses confirmed the diagnosis of HLRCC. Despite adjuvant pembrolizumab therapy after nephrectomy, bone metastases were detected within 9 weeks. The patient was treated with stereotactic body radiotherapy (SBRT), followed by systemic therapy with nivolumab and cabozantinib. After 16 months since the recurrence, no further disease progression was observed. Genetic counseling revealed the same FH mutation in her daughter, prompting annual surveillance.
Conclusion
This case highlights the potential efficacy of combining tyrosine kinase inhibitor therapy with SBRT in managing aggressively progressive HLRCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
- Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan, tomonori.sato.d4@tohoku.ac.jp.
- Department of Pathology, Tohoku University Hospital, Sendai, Japan.
- Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
Zitieren
APA
Masuda, H., Sato, T., Sato, S., Goto, T., Katayama, H., Satake, Y., Sato, T., Kawasaki, Y., Kawamorita, N., Shirota, H., & Ito, A. (2025). Course of Multimodal Therapy and Genetic Profile of Hereditary Leiomyomatosis and Renal Cell Carcinoma with Early Recurrence during Adjuvant Therapy after Radical Nephrectomy: A Case Report. Urologia Internationalis. https://doi.org/10.1159/000547393
Vancouver
Masuda H, Sato T, Sato S, Goto T, Katayama H, Satake Y, et al. Course of Multimodal Therapy and Genetic Profile of Hereditary Leiomyomatosis and Renal Cell Carcinoma with Early Recurrence during Adjuvant Therapy after Radical Nephrectomy: A Case Report. Urologia Internationalis. 2025. doi:10.1159/000547393
BibTeX
@article{Masuda2025,
author = {Masuda, Hiroshi and Sato, Tomonori and Sato, Satoko and Goto, Takuro and Katayama, Hiromichi and Satake, Yohei and Sato, Takuma and Kawasaki, Yoshihide and Kawamorita, Naoki and Shirota, Hidekazu and Ito, Akihiro},
title = {Course of Multimodal Therapy and Genetic Profile of Hereditary Leiomyomatosis and Renal Cell Carcinoma with Early Recurrence during Adjuvant Therapy after Radical Nephrectomy: A Case Report},
journal = {Urologia Internationalis},
year = {2025},
doi = {10.1159/000547393}
}
EUVIMED